Newron Pharmaceuticals S.p.A.

BRIEF

published on 08/12/2025 at 07:05, 3 months 24 days ago

Newron lance l'étude de phase III ENIGMA-TRS pour la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Traitement De La Schizophrénie Étude De Phase III Thérapie TRS
PRESS RELEASE

published on 08/12/2025 at 07:00, 3 months 24 days ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 08/11/2025 at 07:05, 3 months 25 days ago

L'Evenamide de Newron Pharmaceuticals s'avère prometteur dans le traitement de la schizophrénie

Newron Pharmaceuticals Traitement De La Schizophrénie Recherche Sur L'évenamide Modulation Du Glutamate Étude De Neuropsychopharmacologie
BRIEF

published on 08/11/2025 at 07:05, 3 months 25 days ago

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
PRESS RELEASE

published on 08/11/2025 at 07:00, 3 months 25 days ago

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus
BRIEF

published on 05/12/2025 at 07:05, 6 months 24 days ago

Newron's ENIGMA-TRS Phase III Program Approved for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Treatment-resistant Schizophrenia Glutamatergic Modulation
BRIEF

published on 05/12/2025 at 07:05, 6 months 24 days ago

Le programme ENIGMA-TRS de phase III de Newron approuvé pour le traitement de la schizophrénie résistante au traitement

Newron Pharmaceuticals Evenamide Phase III ENIGMA-TRS Schizophrénie Résistante Au Traitement Modulation Glutamatergique
PRESS RELEASE

published on 05/12/2025 at 07:00, 6 months 24 days ago

Newron announces approval for pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals announces approval for pivotal Phase III ENIGMA-TRS program evaluating evenamide as add-on therapy in treatment-resistant schizophrenia patients. Study results expected in Q4 2026

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 04/01/2025 at 07:05, 8 months 4 days ago

Newron Pharmaceuticals Reports 2024 Financial Results, Previews 2025

Financial Results Evenamide Development Schizophrenia Treatment Licensing Agreements Outlook 2025
BRIEF

published on 04/01/2025 at 07:05, 8 months 4 days ago

Newron Pharmaceuticals publie ses résultats financiers pour 2024 et présente un aperçu de 2025.

Résultats Financiers Développement D'Evenamide Traitement De La Schizophrénie Accords De Licence Perspectives 2025

Published on 12/05/2025 at 02:35, 6 hours 43 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours 48 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 8 hours 18 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 13 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 10 hours 18 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

Published on 12/05/2025 at 09:05, 13 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 17 minutes ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 18 minutes ago

SPECTRIS PLC - Removal
Published on 12/05/2025 at 09:00, 18 minutes ago

Official List Notice
Published on 12/05/2025 at 09:00, 18 minutes ago

Petershill Partners plc - Removal

View all EQS

Published on 12/05/2025 at 08:45, 33 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 33 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 36 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 15 hours 3 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 15 hours 18 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE

News